Other Vaccines - Southern Asia

  • Southern Asia
  • In Southern Asia, the revenue in the market Other Vaccines market is projected to reach US$0.58bn in 2024.
  • It is expected to show an annual growth rate (CAGR 2024-2029) of 11.06%, resulting in a market volume of US$0.98bn by 2029.
  • When comparing globally, United States is expected to generate the highest revenue, with US$24,730.00m in 2024.
  • In Southern Asia, the demand for Other Vaccines is increasing rapidly due to the region's high population density and growing awareness about preventive healthcare.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The demand for Other Vaccines in Southern Asia has been on the rise in recent years due to various factors such as increasing population, rising awareness about the importance of vaccines, and the emergence of new diseases.

Customer preferences:
Customers in Southern Asia are becoming increasingly aware of the importance of vaccines in preventing diseases. This has led to a growing demand for Other Vaccines, which offer protection against a wide range of diseases. In addition, customers in the region are also showing a preference for vaccines that are affordable and easily accessible.

Trends in the market:
The Other Vaccines market in Southern Asia is expected to grow significantly in the coming years due to increasing government initiatives to promote vaccination programs. Countries such as India, Pakistan, and Bangladesh have launched various vaccination campaigns to combat diseases such as polio and measles. This has led to an increase in demand for Other Vaccines in these countries.

Local special circumstances:
In India, the government has launched the Universal Immunization Program (UIP), which aims to provide free vaccines to all children in the country. This has led to a significant increase in demand for Other Vaccines in the country, as parents are becoming more aware of the importance of vaccinating their children. In Pakistan, the government has launched the Expanded Program on Immunization (EPI), which aims to provide free vaccines to all children under the age of five. This has also led to an increase in demand for Other Vaccines in the country.

Underlying macroeconomic factors:
The growing population in Southern Asia is a key driver of the growth in the Other Vaccines market. With a large population, the demand for vaccines is naturally higher. In addition, rising incomes in the region have also contributed to the growth of the market, as more people are able to afford vaccines. The emergence of new diseases in the region has also led to an increase in demand for Other Vaccines. For example, the recent outbreak of COVID-19 has led to a surge in demand for vaccines that offer protection against the virus.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)